WebDoctor Encyclopedia

Adnexal carcinomas

Hidradenocarcinoma

Hidradenocarcinoma is a rare sweat gland cancer of the skin, the malignant form of a hidradenoma. It appears as a firm, growing lump, often on the head and neck in adults around 60, and is treated mainly with wide excision or Mohs surgery.

Medically reviewed Last reviewed October 19, 2026

What is hidradenocarcinoma?

Hidradenocarcinoma is a rare skin cancer that grows from a sweat gland. It is the malignant (cancerous) form of a hidradenoma, a common harmless sweat gland lump that is also called a nodular or clear cell hidradenoma.

It belongs to the adnexal carcinomas, a group of cancers that arise from skin structures such as sweat glands, hair follicles and oil glands.

Hidradenocarcinoma usually appears as a firm, slowly enlarging lump in or under the skin. It is most common on the head and neck, but it also occurs on the trunk, arms and legs (Gao et al., 2022). It mostly affects adults in their 50s to 70s, with an average age of about 60 (Kent et al., 2024).

It can develop on its own or, rarely, from a long-standing benign hidradenoma. Because it looks like many common skin lumps, it is usually diagnosed only after removal and examination under the microscope.

Older reports described hidradenocarcinoma as a very aggressive cancer, with high rates of recurrence and spread. More recent, larger studies suggest that most people do well after complete surgery, although the cancer can come back or spread to lymph nodes in a minority of cases (Gao et al., 2022).

1. Key facts at a glance

Feature Details
Type of cancer Malignant sweat gland (adnexal) carcinoma of the skin
How common Rare; a small fraction of all skin cancers
Typical age Average about 60; range from young adults to the very elderly
Sex Slightly more common in men in some series
Common sites Head and neck (about 4 in 10); trunk, arms and legs
Appearance Firm, red, purple or skin-coloured lump, sometimes ulcerated
Main treatment Wide local excision or Mohs surgery
Typical spread Nearby skin, lymph nodes; less often lungs, bone, liver
Outlook Good for most after complete removal; worse if it has spread

2. Causes and risk factors

The cause of hidradenocarcinoma is not known. Unlike many skin cancers, it is not clearly linked to sun exposure, and it often occurs on skin that is usually covered.

Factor Notes
Age Most people are over 50
Pre-existing hidradenoma Rarely, a benign hidradenoma turns malignant
Weakened immune system May increase risk, as with other skin cancers
Previous radiation Reported in a few cases

Gene changes

Gene change Notes
CRTC1::MAML2 fusion Common in benign hidradenomas and found in a subset of hidradenocarcinomas (Yoshimi et al., 2017)
HER2 (ERBB2) overexpression Seen in some tumours; may open up targeted treatment options
TP53 changes Found in some tumours
PIK3CA and other pathway changes Reported in a minority

These changes arise only in the tumour and are not inherited. Specialised tests for gene changes can help pathologists confirm that a tumour comes from a sweat gland and separate it from other cancers (Macagno et al., 2022).

Tumour Behaviour Notes
Hidradenoma Benign Common, slow-growing lump; often solid and cystic
Poroma Benign Sweat duct tumour, often on the palms or soles
Hidradenocarcinoma Malignant The cancerous counterpart of hidradenoma
Porocarcinoma Malignant The cancerous counterpart of poroma
Microcystic adnexal carcinoma Malignant, locally aggressive Usually on the face; spreads along nerves
Mucinous carcinoma of the skin Malignant, low grade Usually around the eyes

3. How does it look

On the skin

Feature Description
Shape A single, firm, raised lump or nodule, sometimes a deeper swelling
Colour Skin-coloured, red, pink, purple or blue
Surface Smooth, shiny, crusted or ulcerated
Size Usually 1-5 cm, sometimes larger
Growth Often slow, sometimes with a recent spurt of growth
Discharge May ooze clear fluid or bleed
Feel Firm or rubbery; may feel partly fluid-filled

On scans

Ultrasound may show a solid and cystic lump in the skin and the fat beneath. CT, MRI or PET-CT are used if the tumour is large or if spread to lymph nodes or other organs is suspected.

Under the microscope

Feature Description
Structure Nodules and sheets of tumour cells, often with cystic spaces
Cells Clear cells with pale cytoplasm, and polygonal cells with pink cytoplasm
Ducts Small duct-like spaces lined by tumour cells
Malignant features Infiltrative edges, abnormal nuclei, many mitoses, necrosis, invasion of nerves or vessels
Comparison with hidradenoma Hidradenoma is well circumscribed with no infiltration and few mitoses
Special stains Keratins, EMA and CEA in duct structures; p63 often positive; HER2 positive in some

Telling hidradenocarcinoma apart from a benign hidradenoma or from cancer that has spread to the skin from another organ, such as the breast or kidney, can be difficult. Review by an expert dermatopathologist is recommended (Ahn and Sangüeza, 2019).

4. Symptoms

Hidradenocarcinoma usually causes few symptoms apart from the lump.

Common symptoms

  • A firm lump in or under the skin
  • A lump that is growing, sometimes after years of being stable
  • Bleeding or oozing from the lump
  • Ulceration or a sore that does not heal
  • Tenderness or pain in some people
  • Redness or discoloured skin over the lump

Symptoms of spread

Site Possible symptoms
Nearby skin New small lumps around the scar
Lymph nodes Swollen lumps in the neck, armpit or groin
Lungs Cough, breathlessness, chest pain
Bone Bone pain
Liver Tummy discomfort, jaundice (rare)

When to seek medical advice

See a doctor or dermatologist about any lump that is new, growing, bleeding, ulcerated or that has changed after being stable for a long time. Many skin lumps are harmless, but a biopsy is the only way to be sure.

5. Diagnosis

Test Purpose
Skin examination Assesses the lump and nearby lymph nodes
Biopsy or excision Removes tissue for diagnosis; excision of the whole lump is often best
Immunohistochemistry Confirms sweat gland origin and excludes other cancers
Molecular testing MAML2 fusion or HER2 testing in selected cases
Ultrasound of lymph nodes Looks for spread, with needle biopsy if suspicious
Sentinel lymph node biopsy Considered for higher-risk tumours
CT or PET-CT For large or high-risk tumours, or if spread is suspected
Tests to exclude metastasis Breast or kidney imaging when the tumour could be a spread from elsewhere

Why diagnosis is often delayed

Hidradenocarcinoma is often present for months or years before it is diagnosed. There are several reasons:

  • It can look like a cyst, lipoma or benign hidradenoma
  • It often grows slowly and causes no pain
  • A small or shallow biopsy may miss the malignant areas
  • It is rare, so it may not be considered at first

For these reasons, any lump that grows, bleeds or changes should be removed or biopsied, and the whole lesion should be examined where possible.

6. Treatment

Treatment is planned by a skin cancer team that may include dermatologists, Mohs surgeons, plastic surgeons, pathologists and oncologists.

Surgery

Approach Notes
Wide local excision Removes the tumour with a margin of normal tissue, often 1-2 cm
Mohs micrographic surgery Checks every margin under the microscope; may lower the risk of recurrence and is useful on the face and neck (Kent et al., 2024)
Reconstruction Skin grafts or flaps for larger wounds
Re-excision If margins are not clear

Lymph nodes

Situation Approach
High-risk tumour, normal-feeling nodes Sentinel lymph node biopsy may be offered
Cancer in lymph nodes Lymph node dissection, often followed by radiotherapy

Sentinel lymph node biopsy explained

Step What happens
1. Tracer injection A small amount of tracer is injected near the tumour site
2. Mapping A scan and a handheld probe find the first lymph node(s) that drain the area
3. Removal These sentinel nodes are removed through a small cut, usually at the same time as the main surgery
4. Testing The nodes are examined for cancer cells
5. Next steps If cancer is found, further surgery or radiotherapy may be advised

Radiotherapy

Radiotherapy may be given after surgery for close or positive margins, large or high-grade tumours, nerve invasion, or lymph node spread. It can also be used when surgery is not possible and to relieve symptoms of metastases (Soni et al., 2015).

Treatment of advanced disease

There is no standard drug treatment, because the cancer is rare.

Option Notes
Chemotherapy Platinum drugs, capecitabine, taxanes or other regimens; responses are often limited
HER2-targeted drugs Trastuzumab and related drugs have helped some people with HER2-positive tumours
Other targeted drugs Chosen according to gene changes found in the tumour
Immunotherapy Responses to checkpoint inhibitors have been reported in individual patients
Clinical trials Recommended where available

Side effects

Treatment Possible side effects
Skin surgery Pain, scarring, wound infection, slow healing
Lymph node surgery Limb or neck swelling (lymphoedema), numbness, fluid collection
Radiotherapy Skin redness, peeling, tiredness, later skin tightness
Chemotherapy Nausea, tiredness, low blood counts, hair loss, sore hands and feet
Targeted and immune therapy Rash, diarrhoea, heart effects (HER2 drugs), inflammation of organs (immunotherapy)

What treatment involves day to day

Part of treatment What to expect
Excision or Mohs surgery Usually a day case under local anaesthetic
Larger reconstruction or node surgery General anaesthetic and a short hospital stay
Wound care Dressings for 1-2 weeks; stitches out after 1-2 weeks
Radiotherapy Short daily sessions on weekdays over 3-6 weeks

7. Outlook (prognosis)

Measure Approximate figures
Cancer-specific survival at 10 years About 90% in a large US registry study (Gao et al., 2022)
Spread at diagnosis or later Over a third of published cases, which may over-represent severe cases (Kent et al., 2024)
Local recurrence Common in older series, especially after incomplete removal

In the US registry study of 289 people, about 60% were alive at 10 years, but most deaths were from other causes, reflecting the older age of many patients. The cancer itself caused relatively few deaths, and larger tumour size was linked with poorer overall survival (Gao et al., 2022). Older reports of very high recurrence and spread rates may reflect small numbers and severe cases, as well as differences in surgical technique (Gauerke and Driscoll, 2010).

Factors that may be linked with a poorer outlook

  • Large tumour size
  • Incomplete removal
  • High-grade features, such as many mitoses, necrosis or nerve and vessel invasion
  • Lymph node or distant spread

8. Follow-up

Follow-up Purpose
Skin and scar checks Every 3-6 months for the first 2-3 years, then every 6-12 months
Lymph node examination At each visit
Ultrasound or scans For high-risk tumours or new symptoms
Long-term review Recommended for at least 5 years, as late recurrences occur

9. Living with hidradenocarcinoma

  • Check the scar and surrounding skin monthly for new lumps
  • Feel for swollen lymph nodes in the nearest neck, armpit or groin
  • Care for your wound and report redness, swelling or discharge
  • Ask about lymphoedema care if you had lymph node surgery
  • Protect your skin from the sun, especially if you have other skin cancer risk factors
  • Keep a photo record of the scar and nearby skin, so changes are easier to spot
  • Keep a list of questions for each appointment
  • Seek support from rare cancer and skin cancer charities

10. Frequently asked questions

Question Answer
Is hidradenocarcinoma common? No, it is a rare skin cancer
Is it caused by sweating? No. It arises from sweat gland cells, but sweating does not cause it
Is it inherited? No
Can a benign hidradenoma become cancer? Rarely, yes. A changing lump should be checked
Will I need chemotherapy? Usually not; surgery is the main treatment
Can it come back? Yes, sometimes, so follow-up is important
Is it the same as porocarcinoma? No. Both are sweat gland cancers, but they come from different parts of the gland
Why do I need scans? Scans check for spread in larger or higher-risk tumours; small, low-risk tumours may not need them

11. Questions to ask your care team

  • Was the tumour completely removed with clear margins?
  • Does it have any high-risk features?
  • Would Mohs surgery or sentinel lymph node biopsy be helpful?
  • Do I need radiotherapy?
  • Has the tumour been tested for HER2 or other targetable changes?
  • How often will I need check-ups, and for how long?

Resources

  1. Ahn, C.S. and Sangüeza, O.P. (2019) ‘Malignant sweat gland tumors’, Hematology/Oncology Clinics of North America, 33(1), pp. 53-71.
  2. Gao, T. et al. (2022) ‘Prognostic analysis of hidradenocarcinoma: a SEER-based observational study’, Annals of Medicine, 54(1), pp. 454-463.
  3. Gauerke, S. and Driscoll, J.J. (2010) ‘Hidradenocarcinomas: a brief review and future directions’, Archives of Pathology and Laboratory Medicine, 134(5), pp. 781-785.
  4. Kent, S. et al. (2024) ‘Hidradenocarcinoma: a case series from the Scripps Clinic with a systematic review of the literature’, Dermatologic Surgery, 50(6), pp. 507-511.
  5. Macagno, N. et al. (2022) ‘Recent advances on immunohistochemistry and molecular biology for the diagnosis of adnexal sweat gland tumors’, Cancers, 14(3), 476.
  6. Soni, A. et al. (2015) ‘Current management approach to hidradenocarcinoma: a comprehensive review of the literature’, Ecancermedicalscience, 9, 517.
  7. Yoshimi, K. et al. (2017) ‘Translocation of the MAML2 gene in hidradenocarcinoma’, Journal of Dermatology, 44(8), pp. e190-e191.
  8. National Cancer Institute (2026) Skin Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/skin-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.